| Drug Type Monoclonal antibody | 
| Synonyms Imsidolimab (USAN), ANB 019, ANB-019 | 
| Target | 
| Action inhibitors | 
| Mechanism IL-36R inhibitors(Interleukin-36 receptor inhibitors) | 
| Therapeutic Areas | 
| Active Indication- | 
| Inactive Indication | 
| Originator Organization | 
| Active Organization- | 
| Inactive Organization | 
| License Organization | 
| Drug Highest PhaseDiscontinuedPhase 3 | 
| First Approval Date- | 
| RegulationOrphan Drug (United States) | 


| KEGG | Wiki | ATC | Drug Bank | 
|---|---|---|---|
| D11892 | - | - | - | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Generalized Pustular Psoriasis | Phase 3 | China  | 25 May 2023 | |
| Generalized Pustular Psoriasis | Phase 3 | China  | 25 May 2023 | |
| Generalized Pustular Psoriasis | Phase 3 | Australia  | 25 May 2023 | |
| Generalized Pustular Psoriasis | Phase 3 | Australia  | 25 May 2023 | |
| Generalized Pustular Psoriasis | Phase 3 | Malaysia  | 25 May 2023 | |
| Generalized Pustular Psoriasis | Phase 3 | Malaysia  | 25 May 2023 | |
| Generalized Pustular Psoriasis | Phase 3 | South Korea  | 25 May 2023 | |
| Generalized Pustular Psoriasis | Phase 3 | South Korea  | 25 May 2023 | |
| Generalized Pustular Psoriasis | Phase 3 | Taiwan Province  | 25 May 2023 | |
| Generalized Pustular Psoriasis | Phase 3 | Taiwan Province  | 25 May 2023 | 
| Phase 3 | 45 | Imsidolimab 750mg (GEMINI-1) | iftycthans(vqfgrlekrj) = xgfrpzbgki krxqskysmg (igfjdfumdz ) | Positive | 09 May 2024 | ||
| Imsidolimab 300mg (GEMINI-1) | iftycthans(vqfgrlekrj) = bsprrrgizm krxqskysmg (igfjdfumdz ) | ||||||
| Phase 3 | 45 | xaqlzstluf(ihpbmocggh) = tuncaadpks fzqogjrsnh (ehyvjeknjq ) Met View more | Positive | 09 Oct 2023 | |||
| Placebo | xaqlzstluf(ihpbmocggh) = invvtrhttf fzqogjrsnh (ehyvjeknjq ) Met | 






